Shanghai Junshi Bio and Ascentage Pharma of Suzhou joined to test a combination of Junshi’s approved anti-PD-1 therapy and Ascentage’s clinical-stage Inhibitor of Apoptosis Proteins (IAP), APG-1387. The trial will enroll China patients with solid and hematological tumors. In pre-clinical and early clinical tests, the combination of APG-1387 and a PD-1 immunoncology therapy showed strong antitumor activity. Junshi’s Tuoyi (toripalimab) is the first domestically developed PD-1 therapy approved in China.
Source: China Biotoday
